Replies to post #235471 on Biotech Values

[DewDiligence]

Is ASMB now a buy? It depends!

ASMB—$5.15—trading down to cash level...took a first position.

From an investment (rather than trading) perspective, buying now is reasonable if you think one of ASMB’s two follow-on CpAM agents, which are more potent than ABI-H0731, will eventually work out.

On the other hand, I strongly disagree with ASMB’s decision to continue plans for phase-2 and phase-3 trials of ABI-H0731 with other agents in pursuit of the “inadequate chronic suppression” market. Even if adding ABI-H0731 to a regimen nominally succeeds by getting these patients to undetectable viral load, the clinical benefit of such an outcome is unclear and getting reimbursement for such an indication will be a tall order, IMO.

In other words, it looks like ASMB is succumbing to Zebra’s Law.

[RNsidersbuying]

ASMB 5.58 - re-entered here for a second go-round. I'm showing approx. $8 in tangible BV (at 9/30/20) within a broad-market of absolute lunacy in forming hockey-stick-charts.